{"id":"NCT01636206","sponsor":"Shire","briefTitle":"Safety Study of Lifitegrast to Treat Dry Eye","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-16","primaryCompletion":"2014-03-03","completion":"2014-03-03","firstPosted":"2012-07-10","resultsPosted":"2016-10-03","lastUpdate":"2021-06-11"},"enrollment":332,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Disease"],"interventions":[{"type":"DRUG","name":"Lifitegrast","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Lifitegrast","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1 year.","primaryOutcome":{"measure":"Number of Participants With Ocular and Nonocular Treatment Emergent Adverse Events (TEAEs) for 1 Year","timeFrame":"Day 0 to Day 360","effectByArm":[{"arm":"Placebo","deltaMin":38,"sd":null},{"arm":"Lifitegrast","deltaMin":118,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":23,"countries":["United States"]},"refs":{"pmids":["27055211"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":111},"commonTop":["Instillation site irritation","Dysgeusia","Visual acuity reduced","Instillation site reaction","Dry eye"]}}